Skip to content

Ardelyx ARDX Non-Cash Interest Expense Related To Sale Of Royalties

Non-Cash Interest Expense Related To Sale Of Royalties at other companies

Nektar Therapeutics logo
Nektar TherapeuticsNKTR
$7.94M+59.7%
Ultragenyx Pharmaceutical logo
Ultragenyx PharmaceuticalRARE
$21M+50.0%
Ultragenyx Pharmaceutical logo
Ultragenyx PharmaceuticalRARE
$21M+50.0%
Geron logo
GeronGERN
$3.91M-18.5%
Omeros logo
OmerosOMER
-$1.41M+58.2%
BioCryst Pharmaceuticals logo
BioCryst PharmaceuticalsBCRX
$13.29M-1.6%

Other financials

Income statement

See full
Revenue$94.5M+27.5%
Gross profit$89.7M+45.1%
Operating income-$32.8M+9.8%
Net income-$37.6M+8.6%
EPS (diluted)-$0.15+11.8%

Balance sheet

See full
Cash & equivalents$31.2M+1.3%
Total debt$208.3M+34.3%
Total equity$148.6M+2.0%
Total assets$504.5M+23.0%

Cash flow

See full
Operating cash flow-$32.2M+16.2%
CapEx$69.0K-78.8%
Free cash flow-$32.3M+16.7%

Valuation

See full
Market cap$1.53B+75.8%
Enterprise value$1.71B+71.5%
P/S3.6×+1.2×

Profitability

See full
Gross margin92.5%+7.9pp
Operating margin-25.4%
Net margin-13.6%
FCF margin-40.9%

Returns & leverage

See full
Return on equity-39.5%
Debt / equity1.4×+0.3×
Current ratio3.5×-0.6×

Where this comes from

Reported directly by Ardelyx in its filing.

Tagged under the XBRL concept ardx:NonCashInterestExpenseRelatedToSaleOfRoyalties.

The official record: Ardelyx’s 10-Q, filed April 30, 2026, on SEC EDGAR. View the filing →

Ask your AI about Ardelyx's non-cash interest expense related to sale of royalties.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude

Questions, answered.

What is Ardelyx's non-cash interest expense related to sale of royalties?
Ardelyx (ARDX) reported non-cash interest expense related to sale of royalties of $1.32M in Q1 2026.
How has Ardelyx's non-cash interest expense related to sale of royalties changed year-over-year?
Ardelyx's non-cash interest expense related to sale of royalties decreased by 36.4% year-over-year, from $2.07M to $1.32M.
What is the long-term trend for Ardelyx's non-cash interest expense related to sale of royalties?
Over 3 years (2022 to 2025), Ardelyx's non-cash interest expense related to sale of royalties has grown at a 70.5% compound annual growth rate (CAGR), from $1.67M to $8.3M.
What does non-cash interest expense related to sale of royalties mean?
This metric captures the non-cash interest expense recognized in connection with royalty monetization agreements or similar financing arrangements where future revenue streams are sold. It reflects the amortization of liabilities associated with upfront capital received in exchange for future royalty payments. Investors track this to understand the impact of non-cash financing costs on the company's reported earnings and to assess the long-term cost of capital derived from royalty-based funding.